<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Vosoritide: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Vosoritide: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Vosoritide: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_pediatric" data-topicid="134443" href="/d/html/134443.html" rel="external">see "Vosoritide: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F56412813"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Voxzogo</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F56393315"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        C-type Natriuretic Peptide</li></ul></div>
<div class="block dop drugH1Div" id="F56413012"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="134443" href="/d/html/134443.html" rel="external">see "Vosoritide: Pediatric drug information"</a>)</p>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Adjust dose based on actual body weight as patient grows; vial strength and resultant concentration varies based on patient weight. Permanently discontinue upon closure of epiphyses.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0c884f4d-8ee3-4ef7-8694-585e5f901914">Achondroplasia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Achondroplasia: Note:</b> Ensure patient is well hydrated and has adequate food intake 1 hour prior to dose to reduce the risk of low blood pressure and related symptoms (eg, dizziness, fatigue, nausea).</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥5 years and Adolescents: SUBQ:</p>
<table border="1" frame="border" rules="all" style="margin-left:6em;">
<caption style="text-align:left;">
<b>Vosoritide Dosing</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead valign="top">
<tr>
<th align="left">
<p style="text-indent:0em;">
<b>Actual Body Weight</b></p></th>
<th align="left">
<p style="text-indent:0em;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;">Injection Volume</p></th>
<th align="left">
<p style="text-indent:0em;">
<b>Frequency of Dosing </b></p></th>
<th align="left">
<p style="text-indent:0em;">
<b>Vial Strength Needed for Reconstitution</b></p></th>
<th align="left">
<p style="text-indent:0em;">
<b>Reconstituted Concentration</b></p></th></tr></thead>
<tbody valign="top">
<tr>
<td align="left">
<p style="text-indent:0em;">10 to &lt;12 kg</p></td>
<td align="left">
<p style="text-indent:0em;">0.24 mg</p></td>
<td align="left">
<p style="text-indent:0em;">0.3 mL</p></td>
<td align="left">
<p style="text-indent:0em;">Once daily</p></td>
<td align="center">
<p style="text-indent:0em;">0.4 mg/vial</p></td>
<td align="center">
<p style="text-indent:0em;">0.8 mg/mL</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">12 to &lt;17 kg</p></td>
<td align="left">
<p style="text-indent:0em;">0.28 mg</p></td>
<td align="left">
<p style="text-indent:0em;">0.35 mL</p></td>
<td align="left">
<p style="text-indent:0em;">Once daily</p></td>
<td align="center" rowspan="3" valign="middle">
<p style="text-indent:0em;">0.56 mg/vial</p></td>
<td align="center" rowspan="3" valign="middle">
<p style="text-indent:0em;">0.8 mg/mL</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">17 to &lt;22 kg</p></td>
<td align="left">
<p style="text-indent:0em;">0.32 mg</p></td>
<td align="left">
<p style="text-indent:0em;">0.4 mL</p></td>
<td align="left">
<p style="text-indent:0em;">Once daily</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">22 to &lt;33 kg</p></td>
<td align="left">
<p style="text-indent:0em;">0.4 mg</p></td>
<td align="left">
<p style="text-indent:0em;">0.5 mL</p></td>
<td align="left">
<p style="text-indent:0em;">Once daily</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">33 to &lt;44 kg</p></td>
<td align="left">
<p style="text-indent:0em;">0.5 mg</p></td>
<td align="left">
<p style="text-indent:0em;">0.25 mL</p></td>
<td align="left">
<p style="text-indent:0em;">Once daily</p></td>
<td align="center" rowspan="4" valign="middle">
<p style="text-indent:0em;">1.2 mg/vial</p></td>
<td align="center" rowspan="4" valign="middle">
<p style="text-indent:0em;">2 mg/mL</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">44 to &lt;60 kg</p></td>
<td align="left">
<p style="text-indent:0em;">0.6 mg</p></td>
<td align="left">
<p style="text-indent:0em;">0.3 mL</p></td>
<td align="left">
<p style="text-indent:0em;">Once daily</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">60 to &lt;90 kg</p></td>
<td align="left">
<p style="text-indent:0em;">0.7 mg</p></td>
<td align="left">
<p style="text-indent:0em;">0.35 mL</p></td>
<td align="left">
<p style="text-indent:0em;">Once daily</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">≥90 kg</p></td>
<td align="left">
<p style="text-indent:0em;">0.8 mg</p></td>
<td align="left">
<p style="text-indent:0em;">0.4 mL</p></td>
<td align="left">
<p style="text-indent:0em;">Once daily</p></td></tr></tbody></table></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F56413020"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function:</b> Children ≥5 years and Adolescents: SUBQ:</p>
<p style="text-indent:-2em;margin-left:4em;">eGFR ≥60 mL/minute/1.73 m<sup>2</sup>: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">eGFR &lt;60 mL/minute/1.73 m<sup>2</sup>: Use not recommended.</p></div>
<div class="block dohp drugH1Div" id="F56413021"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block arsc drugH1Div" id="F56626634"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Decreased blood pressure</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Mild, transient <b>decreased blood pressure</b> was commonly observed in clinical trials and may be associated with <b>dizziness</b>, <b>fatigue</b>, and/or nausea (all cases were deemed inconsequential and were self-limiting) (Savarirayan 2020). Resolution occurred within a median of 31 minutes (range: 5 to 90 minutes). Patients with significant cardiac/vascular disease or taking antihypertensive medications were excluded from clinical trials.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Dose-related; related to the pharmacologic action. Vosoritide is structurally similar to atrial natriuretic peptide and may result in vascular side effects (Duggan 2021; Savarirayan 2020).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Rapid; median onset 31 minutes (range: 18 to 120 minutes).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Inadequate food and/or fluid intake prior to administration</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F56412876"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse reactions reported in children and adolescents.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Decreased blood pressure (13%)<span class="lexi-table-link-container"> (<a aria-label="Decreased Blood Pressure table link" class="lexi-table-link" data-table-id="lexi-content-decreased-blood-pressure" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-decreased-blood-pressure')">table 1</a>)</span><span class="table-link" style="display:none;">Decreased Blood Pressure</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Decreased Blood Pressure" frame="border" id="lexi-content-decreased-blood-pressure" rules="all">
<caption style="text-align:left;">
<b>Vosoritide: Adverse Reaction: Decreased Blood Pressure</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Vosoritide)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Vosoritide)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">13%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">60</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">61</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Urticaria at injection site (25%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Gastroenteritis (13%), vomiting (27%)</p>
<p style="text-indent:-2em;margin-left:4em;">Immunologic: Antibody development (35%)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Erythema at injection site (75%), injection site reaction (85%; including bleeding at injection site, bruising at injection site, induration at injection site, injection site pruritus, pain at injection site, skin discoloration at injection site), swelling at injection site (62%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia (15%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Xeroderma (5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Diarrhea (10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Seasonal allergy (7%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Influenza (10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Dizziness (10%)<span class="lexi-table-link-container"> (<a aria-label="Dizziness table link" class="lexi-table-link" data-table-id="lexi-content-dizziness" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-dizziness')">table 2</a>)</span><span class="table-link" style="display:none;">Dizziness</span>, fatigue (8%)<span class="lexi-table-link-container"> (<a aria-label="Fatigue table link" class="lexi-table-link" data-table-id="lexi-content-fatigue" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-fatigue')">table 3</a>)</span><span class="table-link" style="display:none;">Fatigue</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Dizziness" frame="border" id="lexi-content-dizziness" rules="all">
<caption style="text-align:left;">
<b>Vosoritide: Adverse Reaction: Dizziness</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Vosoritide)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Vosoritide)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">10%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">60</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">61</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Fatigue" frame="border" id="lexi-content-fatigue" rules="all">
<caption style="text-align:left;">
<b>Vosoritide: Adverse Reaction: Fatigue</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Vosoritide)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Vosoritide)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">8%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">60</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">61</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Otic: Otalgia (10%)</p></div>
<div class="block coi drugH1Div" id="F56393219"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">There are no contraindications listed in the manufacturer's labeling.</p></div>
<div class="block war drugH1Div" id="F56437204"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Dosage form specific issues:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson 2002; Lucente 2000; Shelley 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade 1986; CDC 1984). See manufacturer's labeling.</p></div>
<div class="block foc drugH1Div" id="F56412814"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Subcutaneous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Voxzogo: 0.4 mg (1 ea); 0.56 mg (1 ea); 1.2 mg (1 ea) [contains polysorbate 80]</p></div>
<div class="block geq drugH1Div" id="F56412812"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F56445031"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (Voxzogo Subcutaneous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.4 mg (per each): $1,186.56</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.56 mg (per each): $1,186.56</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1.2 mg (per each): $1,186.56</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block admp drugH1Div" id="F56413023"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Parenteral: SUBQ: Ensure patient has adequate food and liquid intake (240 to 300 mL [8 to 10 ounces]) within 1 hour prior to administration (to reduce the risk of low blood pressure and associated symptoms). Administer SUBQ into the thigh (front middle part), lower abdomen (≥2 inches from navel), back of upper arm, or top of the buttocks. Rotate injection sites; the same injection area should not be used on 2 consecutive days. Administer at the same time each day. Do not inject into sites that are red, swollen, or tender.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Missed doses</i>: Administer dose as soon as possible; if the next scheduled dose is due in &lt;12 hours, skip the missed dose and resume the regular dosing schedule.</p></div>
<div class="block use drugH1Div" id="F56393218"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Achondroplasia:</b> To increase linear growth in pediatric patients with achondroplasia who are ≥5 years of age with open epiphyses.</p></div>
<div class="block cyt drugH1Div" id="F56425523"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F56425520"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Alfuzosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amifostine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Amifostine.  Management: When used at chemotherapy doses, hold blood pressure lowering medications for 24 hours before amifostine administration. If blood pressure lowering therapy cannot be held, do not administer amifostine. Use caution with radiotherapy doses of amifostine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amisulpride (Oral): May enhance the hypotensive effect of Hypotension-Associated Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antipsychotic Agents (Second Generation [Atypical]): Blood Pressure Lowering Agents may enhance the hypotensive effect of Antipsychotic Agents (Second Generation [Atypical]). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Arginine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Barbiturates: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Benperidol: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Blood Pressure Lowering Agents: May enhance the hypotensive effect of Hypotension-Associated Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brimonidine (Topical): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromperidol: May diminish the hypotensive effect of Blood Pressure Lowering Agents. Blood Pressure Lowering Agents may enhance the hypotensive effect of Bromperidol.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Diazoxide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DULoxetine: Blood Pressure Lowering Agents may enhance the hypotensive effect of DULoxetine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Herbal Products with Blood Pressure Lowering Effects: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hypotension-Associated Agents: Blood Pressure Lowering Agents may enhance the hypotensive effect of Hypotension-Associated Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levodopa-Foslevodopa: Blood Pressure Lowering Agents may enhance the hypotensive effect of Levodopa-Foslevodopa. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lormetazepam: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Molsidomine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Naftopidil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nicergoline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nicorandil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nitroprusside: Blood Pressure Lowering Agents may enhance the hypotensive effect of Nitroprusside. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Obinutuzumab: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Management: Consider temporarily withholding blood pressure lowering medications beginning 12 hours prior to obinutuzumab infusion and continuing until 1 hour after the end of the infusion.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pentoxifylline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pholcodine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Pholcodine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Phosphodiesterase 5 Inhibitors: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prostacyclin Analogues: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Quinagolide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Silodosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p></div>
<div class="block rep_considerations drugH1Div" id="F56437201"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;display:inline">A phase 2 dose-finding study of vosoritide did not include patients of reproductive potential (Savarirayan 2019).</p></div>
<div class="block pri drugH1Div" id="F56437202"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Adverse events were not observed in animal reproduction studies.</p></div>
<div class="block brc drugH1Div" id="F56437203"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if vosoritide is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and the benefits of treatment to the mother.</p></div>
<div class="block mop drugH1Div" id="F56437208"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Monitor body weight, growth, and physical development every 3 to 6 months; monitor for epiphyseal closure. Signs and symptoms of low BP (eg, dizziness, fatigue, nausea); BP (as clinically appropriate).</p></div>
<div class="block pha drugH1Div" id="F56437207"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Vosoritide is a C-type natriuretic peptide analog that binds to natriuretic peptide receptor-B and indirectly antagonizes downstream signaling from mutant fibroblast growth factor receptor 3 (FGFR3) via inhibition of extracellular signal-regulated kinases 1 and 2 in the mitogen-activated protein kinase pathway at the level of rapidly accelerating fibrosarcoma serin/threonine protein kinase. Antagonism of the mutant form of FGFR3 (which negatively regulates endochondral bone growth in achondroplasia) results in positive regulation/promotion of chondrocyte proliferation and differentiation.</p></div>
<div class="block phk drugH1Div" id="F56412999"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: Children ≥5 years and Adolescents ≤13 years: Mean range: 2.88 ± 2.45 to 3.02 ± 1.98 L/kg.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Degrades into small peptide fragments and amino acids via catabolic pathways.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Children ≥5 years and Adolescents ≤13 years: Mean range: 21 ± 4.7 to 27.9 ± 9.9 minutes.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak: Children ≥5 years and Adolescents ≤13 years: SUBQ: Median: 15 minutes.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F56522416"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Voxzogo</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Voxzogo</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Voxzogo</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Voxzogo</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Voxzogo</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Voxzogo</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Voxzogo</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Voxzogo</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Voxzogo</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Voxzogo</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Voxzogo</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Voxzogo</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Voxzogo</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Voxzogo</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Voxzogo</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-3960626">
<a name="3960626"></a>Alade SL, Brown RE, Paquet A. Polysorbate 80 and E-Ferol toxicity. <i>Pediatrics.</i> 1986;77(4):593-597.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vosoritide-drug-information/abstract-text/3960626/pubmed" id="3960626" target="_blank">3960626</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6423951">
<a name="6423951"></a>Centers for Disease Control (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product.<i> MMWR Morb Mortal Wkly Rep</i>. 1984;33(14):198-199. <a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm" target="_blank">http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm</a>
<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vosoritide-drug-information/abstract-text/6423951/pubmed" id="6423951" target="_blank">6423951</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12534540">
<a name="12534540"></a>Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. <i>Contact Dermatitis</i>. 2002;47(5):312-313.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vosoritide-drug-information/abstract-text/12534540/pubmed" id="12534540" target="_blank">12534540</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10985636">
<a name="10985636"></a>Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. <i>Contact Dermatitis</i>. 2000;43(3):172.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vosoritide-drug-information/abstract-text/10985636/pubmed" id="10985636" target="_blank">10985636</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31269546">
<a name="31269546"></a>Savarirayan R, Irving M, Bacino CA, et al. C-type natriuretic peptide analogue therapy in children with achondroplasia. <i>N Engl J Med</i>. 2019;381(1):25-35. doi:10.1056/NEJMoa1813446<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vosoritide-drug-information/abstract-text/31269546/pubmed" id="31269546" target="_blank">31269546</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7746084">
<a name="7746084"></a>Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. <i>Lancet</i>. 1995;345(8980):1312-1313.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vosoritide-drug-information/abstract-text/7746084/pubmed" id="7746084" target="_blank">7746084</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Voxzogo (vosoritide) [prescribing information]. Novato, CA: BioMarin Pharmaceutical Inc; November 2021.</div>
</li></ol></div><div id="topicVersionRevision">Topic 134442 Version 39.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
